Simplex Trading’s Elicio Therapeutics ELTX Stock Holding History

Simplex Trading’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-103	Closed	-$935	–	8911
2025 Q3	$1K	Buy	+103	New	+$1.04K	﹤0.01%	8795

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Simplex Trading's ELTX Position: Q4 2025 in Review

Simplex Trading sold out of Elicio Therapeutics (ELTX) in Q4 2025, closing a stake of 103 shares — an estimated $935 sold.

Simplex Trading first reported a position in ELTX in Q3 2025 and held it in 1 quarter. The position peaked at $1K in Q3 2025. 37 funds tracked by Wall St. Rank hold ELTX as of Q4 2025.

Simplex Trading reported no remaining Elicio Therapeutics position as of Q4 2025 after selling out during the quarter.
Simplex Trading sold 103 Elicio Therapeutics shares in Q4 2025, an estimated $935.
Simplex Trading first reported a position in Elicio Therapeutics in Q3 2025 and held it in 1 quarter.
Simplex Trading's Elicio Therapeutics position peaked at $1K in Q3 2025.
37 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.